Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/03/19/2848739/0/en/DepYmed-Receives-Clearance-from-U-S-Food-and-Drug-Administration-to-Initiate-Phase-1-Clinical-Trial-for-DPM-1003-for-the-Treatment-of-Rett-Syndrome.html
https://www.globenewswire.com//news-release/2024/02/21/2832861/0/en/DepYmed-to-Meet-with-Investors-at-the-BIO-CEO-and-Investor-Conference.html
https://www.globenewswire.com//news-release/2024/02/07/2825316/0/en/DepYmed-to-Meet-with-Investors-at-the-34th-Annual-Oppenheimer-Healthcare-Life-Sciences-Conference.html
https://www.globenewswire.com//news-release/2023/10/03/2753800/0/en/DepYmed-to-Meet-with-Investors-at-the-Life-Sciences-Summit-in-New-York-City-October-11-2023.html
https://www.globenewswire.com//news-release/2023/09/27/2750519/0/en/DepYmed-to-Meet-with-Investors-at-the-BioFuture-Conference-in-New-York-City-October-4-6-2023.html
https://www.globenewswire.com//news-release/2023/09/08/2740156/0/en/DepYmed-to-Meet-with-Investors-at-the-LSX-World-Congress-USA-in-Boston-on-September-13-14-2023.html
https://www.globenewswire.com/news-release/2023/06/15/2688935/0/en/DepYmed-Presents-Development-Update-for-its-Small-Molecule-PTP1B-Inhibitor-Program-DPM-1003-at-the-2023-IRSF-Rett-Syndrome-Scientific-Meeting.html
https://www.globenewswire.com/news-release/2023/05/31/2679528/0/en/DepYmed-to-Present-Early-Data-on-Its-Small-Molecule-PTP1B-Inhibitor-Program-at-the-2023-IRSF-Rett-Syndrome-Scientific-Meeting.html
https://www.globenewswire.com/news-release/2022/11/16/2557356/0/en/DepYmed-Receives-European-Medicines-Agency-Orphan-Drug-Designation-for-Its-Lead-Clinical-Candidate-for-the-Treatment-of-Rett-Syndrome.html
https://www.globenewswire.com/news-release/2022/05/23/2448550/0/en/DepYmed-Receives-FDA-Orphan-Drug-Designation-for-Clinical-Candidate-DPM-1001-for-the-Treatment-of-Wilson-Disease.html